ATRN 119
Alternative Names: ATRN-119Latest Information Update: 12 Nov 2024
Price :
$50 *
At a glance
- Originator Atrin Pharmaceuticals
- Class Antineoplastics; Macrocyclic compounds; Small molecules
- Mechanism of Action ATR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 07 Nov 2024 Updated adverse events data from a phase I/II trial in Solid tumour released by Atrin Pharmaceuticals
- 28 May 2024 Pharmacokinetics data from phase I/IIa trial in Solid tumours released by Aprea Therapeutics
- 14 May 2024 Pharmacokinetics data from a phase I/II ABOYA-119 trial in Solid tumours released by Aprea Therapeutics